Skip to content
Screener
Tvardi Therapeutics logo

Tvardi Therapeutics

TVRD

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies that target the Signal Transducer and Activator of Transcription 3 (STAT3) protein.

Market cap
$18.81M-52.7%

Earnings

Q3 2026 report

November 12, 2026

Next report

Date not yet announced

Competitors

Profile

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing novel, oral, small molecule therapies that target the Signal Transducer and Activator of Transcription 3 (STAT3) protein. The company focuses on treating inflammatory and proliferative diseases by directly inhibiting the canonical STAT3 pathway to modulate immune dysregulation and cellular survival. Their platform is designed to block disease-driving transcription without impairing essential mitochondrial functions.

Competitive position

Clinical-stage developer of first-in-class STAT3 inhibitors with Orphan Drug and Fast-Track designations for lead assets.

GeographiesUnited States
Customer segmentsPatients, Healthcare providers
Business modelBiotechnology R&D, Drug development
SuppliersContract research organizations (CROs), Raw material suppliers for small molecule synthesis, Clinical trial sites and investigators
CustomersSpecialty pharmacies, Hospitals, Oncology centers
Listed2025
CEOImran Alibhai
FilingsSEC EDGAR

FAQ

What is Tvardi Therapeutics's market cap?
Tvardi Therapeutics (TVRD) has a market capitalization of $18.8M and trades on NASDAQ.
Who are Tvardi Therapeutics's competitors?
Tvardi Therapeutics's key competitors include Kymera Therapeutics, Rein Therapeutics, Inc. Common Stock, Instil Bio, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Where is Tvardi Therapeutics headquartered?
Tvardi Therapeutics is headquartered in United States of America. It has been publicly traded since 2025.